



Republic of the Philippines  
Department of Health

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2018-171-B  
08 August 2018

RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT FOR ITEM NO. 1 FOR THE  
PROCUREMENT OF METHOTREXATE-REBID  
IB NO. 2018-170-A

WHEREAS, Open Competitive Bidding for the Procurement of Methotrexate-Rebid was conducted in accordance with Republic Act (RA) 9184 and its 2016 Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2018 with a Total Approved Budget for the Contract (ABC) of Five Million Two Hundred Sixty Nine Thousand Eight Hundred Fifty Five Philippine Pesos (Php5,269,855.00):

Item No.	Description	Qty.	Unit	Total ABC (Php)
1	Methotrexate 1gram	780	Vial	3,869,775.00
2	Methotrexate 2.5mg	148,000	Tablet	1,400,080.00
TOTAL				5,269,855.00

WHEREAS, the COBAC Resolution No. 2018-171 "Declaration of Failure of Bidding for the Procurement of Methotrexate under IB No. 2018-170", was approved;

WHEREAS, on 17 April 2018, a Mandatory Review and Pre-procurement Conference took place as scheduled at 1:00 P.M at the COBAC Conference Room, Department of Health (DOH), to determine the readiness of the procurement at hand;

WHEREAS, on 23 April 2018, the Invitation to Bid was published and posted in the PhilGEPS Website and other conspicuous places within the premises of the DOH. The advertisement of the IB in a newspaper of general nationwide circulation provided in Section 21.2.1 (c) of the 2016 IRR of RA 9184 shall not be required for contracts to be bid with an approved budget of Php10M and below for the procurement of goods;

WHEREAS, a Bid Bulletin No. 1, dated 24 April 2018 was issued to announce the new schedule for the Pre-bidding Conference and Submission and Opening of Bids;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-220 dated 30 April 2018;

WHEREAS, a Bid Bulletin No. 2, dated 07 May 2018 was issued to announce the new schedule for the Pre-bidding Conference;

WHEREAS, on 09 May 2018, a Pre-bidding Conference took place as re-scheduled at 10:00 A.M. at the COBAC Conference Room, DOH, with one (1) prospective bidder attending, namely, Zuellig Pharma Corporation (ZPC);

WHEREAS, on 22 May 2018, the Submission and Opening of Bids took place as re-scheduled at 9:00 A.M. at the COBAC Conference Room, DOH, with one (1) prospective bidder submitting its proposal, namely, Globo Asiatico Enterprises, Inc. (GAEI);

WHEREAS, the first envelope, containing the Eligibility and Technical Document was opened and the presence, completeness and correctness of all the documents were verified by the COBAC-A in the presence of the prospective bidder's representative. Upon examination, GAEI was declared "ELIGIBLE;"

WHEREAS, the second envelope, containing the Financial Proposal was opened and the presence, completeness and correctness of the Financial Documents were verified by the COBAC-A in the presence of the bidder's representative. Upon examination, the lone "ELIGIBLE" bidder, GAEI, was rated "PASSED" and subsequently its proposal was read out publicly and posted in the Abstract of Bid, to wit:

Name of Company				GAEI	
Bid Security				BID SECURING DECLARATION	
Amount				N/A	
Validity				N/A	
REMARKS					
Item No.	Item Description	Qty.	Unit	TOTAL ABC (Php)	BID PRICE AS READ (Php)
1	Methotrexate 1 gram	780	Vial	3,869,775.00	3,869,775.00
2	Methotrexate 2.5mg	148,000	Tablet	1,400,080.00	1,361,600.00
TOTAL				5,269,855.00	5,231,375.00

**WHEREAS**, COBAC Resolution No. 2018-171-A "Declaration of Second (2<sup>nd</sup>) Failure of Bidding for Item No. 2 for the Procurement of Methotrexate-Rebid under IB No. 2018-170-A", was approved;

**WHEREAS**, GAEI was declared as the Single Bidder for the above cited items, subject to further arithmetical review and corrections of the financial bid, if necessary;

**WHEREAS**, the bids for the items listed below were found to be substantially complying:

**Item No. 1 - 780 vials of Methotrexate 1gram**

Bidder No.	Name of Company	ABC (Php)	Bid as Calculated Amount (Php)	% Variance from ABC
1	GAEI	3,869,775.00	3,869,775.00	0%

**Item No. 2 – 148,000 tablets of Methotrexate 2.5mg**

Bidder No.	Name of Company	ABC (Php)	Bid as Calculated Amount (Php)	% Variance from ABC
1	GAEI	1,400,080.00	1,361,600.00	2.74%

**WHEREAS**, on 23 May 2018, the detailed evaluation of the submitted proposals on the legal, technical and financial aspects of the documents of the SCB was undertaken by the designated TWG;

**WHEREAS**, on 14 June 2018, the TWG-Technical submitted the initial report and requested GAEI to clarify on the date of validity on the Certificate of Exclusive Distributorship (CED);

**WHEREAS**, on 19 June 2018, the cited TWG report was presented to COBAC-A during its 24<sup>th</sup> Regular Meeting. Upon deliberation, the COBAC-A was informed by the Secretarial in charge that there is date of validity on the CED;

**WHEREAS**, on the same date, the COBAC-A decided to return to TWG for re-evaluation;

**WHEREAS**, on 11 July 2018, the TWG found GAEI compliant with the bidding requirements and submitted its report;

**WHEREAS**, on 17 July 2018, the cited TWG report was presented to COBAC-A during its 27<sup>th</sup> Regular Meeting. Upon deliberation, the COBAC-A concurred with the TWG and decided to proceed with the post-qualification evaluation upon receipt of post-qualification documents;

**WHEREAS**, on 19 July 2018, a notification was issued to GAEI, requesting for the submission of post-qualification requirements;

**WHEREAS**, on 23 July 2018, GAEI submitted its post-qualification requirements and subsequently was forwarded to the TWG, for evaluation;

**WHEREAS**, on 30 July 2018, the TWG found GAEI "responsive" on its post-qualification documents and submitted their post-qualification report;

**WHEREAS**, on 02 August 2018, the TWG Reports was presented to COBAC-A during its 29<sup>th</sup> Regular Meeting concurred with the TWG report and recommended the award of contract in favor of GAEI for Item No. 1;

**WHEREAS**, on 07 August 2018, the TWG submitted the Bid Evaluation and Post Qualification Evaluation Reports citing GAEI "responsive" on the submitted documents;

**WHEREAS**, the COBAC-A reviewed and deliberated the TWG reports, as well as the documents submitted by GAEI. The following are the salient points of discussion:

Item No.	Description	Name of Bidder	Bidder's Rank	ABC (Php)	Bid Price (Php)	TWG		COBAC	
						Finding	Recommendation	Finding	Recommendation
1	Methotrexate 1gram	GAEI	SCB	3,869,775.00	3,869,775.00	The SCB passed the post qualification and found to have complied with the legal, technical and financial requirements.	Responsive	<ul style="list-style-type: none"> <li>COBAC conforms with the recommendation of the TWG.</li> <li>GAEI is determined to be qualified and recommended for the award of contract for Item No. 1.</li> </ul>	Single Calculated and Responsive Bid (SCRB)

WHEREAS, at the time of the signing of this resolution, there is no pending incident, no pending Motion for Reconsideration, no pending Protest and the COBAC-A followed the requirements set forth in R.A. 9184;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A HEREBY RESOLVE to recommend the award of contract to **Globo Asiatico Enterprises, Inc.** determined as the SCRB with a Total Contract Price of **Three Million Eight Hundred Sixty Nine Thousand Seven Hundred Seventy Five Philippine Pesos (Php3,869,775.00)** inclusive of other taxes for the item listed below:

Item No.	Particular	Qty.	Unit	Total Amount (Php)
1	Methotrexate 1gram	780	Vial	3,869,775.00

**AUG 20 2018**

Signed this \_\_\_\_ day of \_\_\_\_ 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

**CENTRAL OFFICE BIDS AND AWARDS COMMITTEE - A**

**LEONTIA P. GORGOLON, MHA, MCHM, CEO VI**  
Regular Member

**FERCHITO L. AVELINO, MD, PHSAE**  
Regular Member

**KENNETH G. RONQUILLO, MD, MPH, CESO III**  
Vice-Chairperson

**MAR WYNN Q. BELLO, MD, MPA**  
Regular Member

**NESTOR F. SANTIAGO, JR., MD, MPH, MHA, CESO III**  
Assistant Secretary of Health  
Chairperson

By Authority of the Secretary of Health:

**MYRNA C. CABOTAJE, MD, MPH, CESO III**  
Director IV  
Disease Prevention and Control Bureau

**SEP 05 2018**